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1. Introduction 
Thromboxane A2 is a new, unstable bioregulator 
which induces the platelet release reaction, platelet 
aggregation a d smooth muscle contractions [ 1 ]. An 
enzyme catalyzing the conversion of prostaglandin 
endoperoxides to thromboxanes (thromboxane syn- 
thase) has been isolated from platelet microsomes [2] 
and the inhibition of this enzyme by various com- 
pounds has been investigated [3]. In addition to 
thromboxane (TX)B~, 12L-hydroxy-5,8,10-hepta- 
decatrienoic acid (HHT) was enzymatically formed 
from prostaglandin (PG)H2 by platelet microsomes 
and purified thromboxane synthase [2]. The present 
paper provides evidence that TXB2 and HHT are 
formed by the same enzyme. It also shows that the 
formation of HHT does not involve TXA2 as an inter- 
mediate. 
2. Materials and methods 
Human platelet microsomes, partially purified 
Abbreviations: APA, 9a,1 lc~-_azo-15(S)hydroxyprosta-5(cis)- 
13(trans)-dienoic a.._cid; EMPA, 9a,1 la-e_poxy-methano-15 (S) 
hydroxyprosta-5 (cis)-i 3 (trans)-dienoic acid; GLC-MS, gas -
liquid chromatography - _mass A~ectrometry; HHD, 12L- 
hydroxy-8,10-heptadecadienoic acid; HHT, 12L-hydroxy- 
5,8,10-heptadecatfienoic acid; L-8027, 2-isopropyl-3-nico- 
tinylindole; N-0164, p -benzyl-4 [ 1 -oxo -2 -(4 -chlorobenzyl)-3 - 
phenylpropyl] phenyl phosphonate; PG, p_rostaglandin; TLC, 
thin-layer c_hromatography; TX, t_hromboxane 
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thromboxane synthase, [1A4C]PGHI (spec. act. 
0.34 Ci/mol) and [1A4C]PGH2 (spec. act. 1.0 Ci/mol) 
were prepared as described [2]. The endoperoxides 
moved slightly ahead of PGB1 on silica gel G thin- 
layer chromatography (TLC) and were converted to 
PGFla and PGF2a, respectively, by SnCI2 reduction. 
9a,1 la-Azo-15(S)hydroxyprosta-5(eis), 13(trans)- 
dienoic acid (APA) was generously given by Dr E. J. 
Corey. 9a,11 a-Epoxymethano-15(S)hydroxyprosta- 
5(cis), 13(trans)-dienoic acid (EMPA) and TXB2 were 
kindly provided by the Upjohn Company. 2-Iso- 
propyl-3-nicotinylindole (L-8027) and sodium 
p-benzyl-4- [ 1 -oxo-2-(4-chlorobenzyl)-3-phenylpropyl] 
phenyl phosphonate (N-0164) were given by Labaz 
and Nelson Research, respectively. Imidazole and 
SnC12 were purchased from Sigma. 
2.1. Analyses of products formed from prostaglandin 
endoperoxides 
Partially purified thromboxane synthase in 0.1 M 
Tris-HC1, pH 7.4, was incubated at 24°C with [lJ4C] - 
PGHI (154 #M) or [1A4C] PGH2 (120/~M). Reactions 
were interrupted after 1 min by addition of cold 0.2 M 
citric acid and products were immediately extracted 
with diethyl ether. After conversion to methyl esters 
aliquots were analyzed by TLC (solvent systems: 
(a) diethyl ether/methanol 49:1 v/v; (b) and (c) the 
organic phases of ethyl acetate/2,2,4-trimethylpentane/ 
water 50:100:100 and 75:75:100 v/v/v, respectively). 
The remainder of the products was further converted 
to trimethylsilyl ether derivatives and analyzed by gas- 
liquid chromatography (1% OV-1) - mass spectrometry 
(GLC-MS). 
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2.2. Enzyme inhibition experiments 
Incubations were performed at twice the scale 
described before [3]. Extracts were divided into two 
parts, for the determination f TXB2 and HHT, 
respectively. Unlabeled TXB2 was added as an internal 
reference for the former analyses. Methylated samples 
were analyzed by TLC using solvents (a) and (b) 
(section 2.1) for TXB2 and HHT determinations, 
respectively. 
Radioactivity on thin-layer chromatograms was 
determined as described [3]. 
2.3. Trapping of thromboxane A 2 
Partially purified thromboxane synthase in 0.1 M 
Tris-HC1, pH 7.4, was incubated at 37°C with [1-14C] - 
PGH2 (120/aM). Reactions were stopped after either 
10 s or 2 min by the addition of 80 vol. methanol to 
convert TXA2 to O-methyl TXB2 [4]. After 1 h at 
24°C, the methanol was removed in vacuo, water was 
added and the products were extracted with diethyl 
ether. Parallel incubations were stopped by adding 
5 vol. SnC12 in ethanol (5 mg/ml) to reduce PGH2 to 
PGF2a [5]. In this case, products were extracted 
after 2 rain at 24°C. Ether extracts were methylated 
and analyzed by TLC, using solvents (a-c) (section 
2.1). For analyses with solvent (a), TXB2 was added 
prior to methylation as an internal reference. 
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Fig. 1. Thin-layer radiochromatograms of products formed 
from [134C]PGHI (upper)and [1-14C]PGH~ (lower)during 
incubations (24°C, 1 min) with partially purified throm- 
boxane synthase from human platelets. HHD, 12-hydroxy-8,10- 
heptadecadienoic ac d; HHT, t 2-hydroxy-5,8,10-hepta- 
decatrienoic a id and TXB~, thromboxane B 2(solvent (a), 
section 2.1 .). 
3. Results 
3.1. Products formed from PGH1 and PGH2 
Figure 1 shows thin-layer radiochromatograms of 
products isolated after incubations of [ 1-14C] PGHI 
(upper panel) and [ 1-14C]PGH2 (lower panel) with 
purified thromboxane synthase from human platelets. 
Based on GLC-MS analyses the major product from 
the first incubation was identified as 2-hydroxy 8,10- 
heptadecadienoic acid (HHD; C-value 19.3; ions at 
m/e 368 (M), 353 (M-15, - CH3), 337 (M-31, • OCH3) ,
321 (M-15-32, • CH3 + CHaOH), 297 (base peak, 
M-71, • CH2(CH2)3CH3), 278 (M-90, (CHa)aSiOH) 
and 225 (M-143, • CH2 (CH2)sCOOCH3)). Small 
amounts of TXB1 (C-value 24.9; ions at m/e 602 (M), 
587 (M-15), 531 (M-71), 512 (M-90), 441 (M-71-90), 
422 (M-2 × 90), 368,325,301,297,258,243 (base 
peak), 217 and 173) were also detected. 
The two major products formed from PGH2 were 
identified as 12-hydroxy-5,8,10-heptadecatrienoic acid 
(C-value 19.2; ions at m/e 366 (M), 351 (M-15), 335 
(M-31), 319 (M-15-32), 295 (base peak, M-71), 276 
(M-90) and 225 (M-141, CH2CH=CH(CH2)3COOCH3)) 
and TXB2 (C-value 24.6; ions at m/e 600 (M), 585 
(M-15), 529 (M-71), 510 (M-90), 439 (M-71-90), 
420 (M-2 × 90), 366,323,301,295,256 (base peak), 
217 and 173), respectively. 
3.2. Inhibition of thromboxane B2, HHT and HHD 
formation 
In a previous tudy data were presented on the 
inhibition of thromboxane synthase by several com- 
pounds [3]. The most potent inhibitors, APA, EMPA, 
L-8027, N-0164 and imidazole, were selected for the 
present investigation. Human platelet microsomes 
were incubated with [1-14C] PGH2 in the presence oi" 
the inhibitors. Two dose-inhibition curves were deter- 
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Fig.2. Linear egression fthe inhibition of thromboxane B 2
and HHT formation by L-8027 (zx), N-0164 (o), imidazole 
(n), 9a,1 la-epoxymethano-15(S)-hydroxyprosta-5(cis), 
13(trans)-dienoic a id (e) and 9a,1 l c~-azo-15 (S)hydroxy- 
prosta-5(cis), 13(trans)-dienoic acid (v). 
mined for each substance, one for TXB2 and one for 
HHT formation. For a given inhibitor these curves 
were always nearly identical. Analogous experiments 
with [1J4C] PGH, as substrate also gave similar dose- 
inhibition curves for HHD formation. In fig.2 the 
inhibition of TXB2 formation has been plotted against 
the inhibition of HHT formation for all five inhibitors. 
Linear regression gave a slope of 0.99, an intercept 
of 1.38 and a coefficient of determination f 0.96. 
3.3. Exclusive trans:ormation of  TXA 2 to TXB2 
PGH2 was incubated with partially purified throm- 
boxane synthase for either 10 s or 2 min at 37°C. The 
reactions were stopped by addition of excess methanol 
to convert TXA2 to O-methyl TXB2. Parallel incuba- 
tions, stopped by addition of SnC12 in ethanol, showed 
that no endoperoxide r mained after 10 s incubation. 
At this time the reaction mixture contained 21% TXA2 
(measured as O-methyl TXB2) 22% TXB2 and 55% 
HHT (fig.3, upper). After 2 min incubation the prod- 
ucts consisted of < 3% TXA2, 42% TXB2 and 55% 
HHT (fig.3, lower). 
500- 
_ 250-  
E 
u 
500 ~ 
250- 
,HHT 
i i 
HHT 
/ TXB 2 
1'5 1'0 
Distance from origin (cm) 
Fig.3. Thin-layer radiochromatograms of products formed 
from [IJ4CJPGH~ during incubations with partially purified 
thromboxane synthase at37°C for 10 s (upper) and 2 min 
(lower). Incubations were stopped by the addition of 80 vol. 
methanol, to convert thromboxane A 2to O-methyl throm- 
boxane B2 (O-Me TXB 2) (Solvent (c), section 2.1 .). 
4. Discussion 
HHD was earlier detected as a by-product of 
prostaglandin biosynthesis in sheep vesicular gland [6]. 
It was suggested to be formed from a prostaglandin 
endoperoxide. The other product of the reaction was 
identified as malondialdehyde [6]. It was later found 
that HHT and TXB2 were formed by aggregating human 
platelets in approximately equal amounts [7]. During 
previous tudies on the solubilization and purification 
of platelet hromboxane synthetase we observed that 
HHT was enzymically formed from PGH2 by the same 
fractions that formed TXB2 [2]. Furthermore, the 
purified enzyme converted PGHI predominantly to
HHD (fig. 1). Five structurally unrelated inhibitors of 
thromboxane formation [3] inhibited TXB2 and HHT 
formation from PGH2 identically (fig.2) and in addi- 
tion inhibited HHD formation from PGH1. These 
results strongly suggest that platelet hromboxane 
synthase catalyzes the conversion of prostaglandin 
endoperoxides to C,7 hydroxy acids plus malondial- 
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(fig. 1). A hypothetical reaction mechanism is outlined 
in fig.4. It is postulated that the isomerization of 
PGH to thromboxane A is initiated by protonation of 
the oxygen at C-9 of the substrate. The cation formed 
after cleavage of the O-O bond can rearrange in two 
ways to yield either thromboxane A or C17 hydroxy 
acid plus malondialdehyde. The results howing that 
TXA2 is exclusively converted to TXB2 has important 
implications for the quantitative determination of
thromboxane synthesis in various biological systems. 
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Fig.4. Possible mechanism of thromboxane A 2 (TXA2), HHT 
and malondialdehyde (MDA) formation from PGH 2, catalyzed 
by thromboxane synthase. 
dehyde. This reaction might or might not involve 
thromboxane A as an intermediate. TXA2 was 
generated uring a short incubation of PGH2 with 
purified thromboxane synthase and the products 
formed during its spontaneous decay were determined 
(fig.3). The results howed that TXA2 was exclusively 
transformed to thromboxane B2 and that HHT was 
formed independently. This is consistent with the pre- 
dominant formation of HHD from PGH1 and the 
approx. 1 : 1 formation of TXB2 and HHT from PGH2 
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